サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1304222

循環無細胞腫瘍DNA市場：腫瘍タイプ別、がんタイプ別、技術別、用途別、地域別- 市場規模、シェア、展望、機会分析、2023年～2030年

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日
ページ情報
英文 190 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
循環無細胞腫瘍DNA市場：腫瘍タイプ別、がんタイプ別、技術別、用途別、地域別- 市場規模、シェア、展望、機会分析、2023年～2030年
出版日: 2023年06月12日
発行: Coherent Market Insights
ページ情報: 英文 190 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

循環腫瘍DNA（ctDNA）とは、血液中を循環する悪性細胞や腫瘍のDNAを指します。細胞の核にDNAの大部分が含まれています。腫瘍が拡大するにつれて細胞は死滅し、新しい細胞と入れ替わる。破壊された死細胞は、DNAを含むその内容物を血流中に排出します。ctDNAは、通常200塩基以下の短いDNAセグメントです。ctDNAの量は人によって異なり、腫瘍の種類、部位、悪性腫瘍の場合は病期によって影響を受ける。循環腫瘍DNA（ctDNA）には通常、がんの検出に有用な遺伝子変化が含まれています。ctDNAのその他の重要な用途としては、予後、治療モニタリング、腫瘍体積の推定などがあります。新しいがん検出検査が、治癒率が最も高い無症状の初期段階でがんを発見することができれば、その臨床的有用性は最大となります。循環腫瘍DNA分析はがんの早期発見に役立ち、分子標的治療薬の提供にも用いられます。

市場力学

製品ポートフォリオを拡大するために、市場の主要企業が製品発売などの有機的成長戦略を採用するケースが増えており、予測期間中の市場成長の原動力になると予想されます。 例えば、2022年7月、次世代分子診断会社のBillionToOne Inc.は、同社初のがん領域リキッドバイオプシー製品であるNorthstar SelectおよびNorthstar Responseの発売を発表しました。この製品は現在、一部の学術がんセンターで研究用として使用可能です。Northstar Selectは包括的な汎がん体細胞変異プロファイリング・パネルです。BillionToOne社独自の分子計数技術、すなわちQCT（Quantitative Counting Templates）を活用したこのパネルは、実用的な変異を同定するための注目すべき検出限界を達成しています。一方、Northstar Responseは、メチル化ベースの組織診断的治療反応モニタリングアッセイです。

本調査の主な特徴

  • 本レポートは、世界の循環無細胞腫瘍DNA市場を詳細に分析し、2022年を基準年とした予測期間（2023-2030年）の市場規模および年間平均成長率（CAGR%）を提供します。
  • また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場に対する魅力的な投資提案のマトリックスについて説明しています。
  • また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
  • 企業ハイライト、製品ポートフォリオ、主なハイライト、業績、戦略などのパラメータに基づいて、世界の循環無細胞腫瘍DNA市場の主要企業をプロファイルしています。
  • この調査の一部としてカバーされている主要企業are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.。
  • 本レポートの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
  • 世界の循環無細胞腫瘍DNA 分析レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
  • 利害関係者は、世界の循環無細胞腫瘍DNA市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概況

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
  • コヒーレント・オポチュニティ・マップ（COM）

第3章 市場力学、規制、動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 主なハイライト
  • 製品発売
  • 技術の進歩
  • PEST分析
  • 規制シナリオ
  • 合併と買収

第4章 循環無細胞腫瘍DNAの世界市場：COVID-19の影響分析

  • 経済的影響
  • COVID-19疫学
  • 需給への影響

第5章 循環無細胞腫瘍DNAの世界市場：腫瘍タイプ別、2018年-2030年

  • 悪性腫瘍
  • 前がん腫瘍

第6章 循環無細胞腫瘍DNAの世界市場：がんタイプ別、2018年～2030年

  • 肺がん
  • 大腸がん
  • 乳がん
  • その他

第7章 循環無細胞腫瘍DNAの世界市場、技術別、2018年～2030年

  • PCR
  • 超並列シーケンス
  • 一塩基多型

第8章 循環無細胞腫瘍DNAの世界市場：用途別、2018年～2030年

  • がん診断
  • 標的治療薬
  • 予後予測

第9章 循環無細胞腫瘍DNAの世界市場：地域別、2018年～2030年

  • 北米
  • 米国
  • カナダ
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
  • 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
  • 中東
  • GCC
  • イスラエル
  • その他中東
  • アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第10章 競合情勢

  • Biocept, Inc.
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • KURABO INDUSTRIES LTD
  • PerkinElmer chemagen Technologie GmbH
  • Biodesix
  • Guardant Health
  • QIAGEN
  • Sequenom, Inc.
  • Agilent Technologies, Inc.
  • Fluxion Biosciences Inc.
  • Natera, Inc.
  • Agena Bioscience, Inc.
  • Paragon Genomics, Inc.
  • Lucence Health Inc.
  • Eurofins Genomics
  • Thermo Fisher Scientific

第11章 セクション

  • 調査手法
  • 出版社について
目次
Product Code: CMI5819

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

  • This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

  • Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
    • Malignant Tumors
    • Precancerous Tumors
  • Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Circulating Cell-Free Tumor DNA Market, By Technology:
    • PCR
    • Massively Parallel Sequencing
    • Single Nucleotide Polymorphism
  • Global Circulating Cell-Free Tumor DNA Market, By Application:
    • Cancer Diagnosis
    • Targeting Therapeutics
    • Prognosis Indication
  • Global Circulating Cell-Free Tumor DNA Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Biocept, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Illumina, Inc.
    • Quest Diagnostics Incorporated
    • KURABO INDUSTRIES LTD
    • PerkinElmer chemagen Technologie GmbH
    • Biodesix
    • Guardant Health
    • QIAGEN
    • Sequenom, Inc.
    • Agilent Technologies, Inc.
    • Fluxion Biosciences Inc.
    • Natera, Inc.
    • Agena Bioscience, Inc.
    • Paragon Genomics, Inc.
    • Lucence Health Inc.
    • Eurofins Genomics
    • Thermo Fisher Scientific

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Tumor Type
    • Market Snapshot, By Cancer Type
    • Market Snapshot, By Technology
    • Market Snapshot, By Application
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Highlights
  • Product Launch
  • Technological Advancements
  • PEST Analysis
  • Regulatory Scenario
  • Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Malignant Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Precancerous Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segments Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segments Trends
  • PCR
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Massively Parallel Sequencing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Single Nucleotide Polymorphism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Cancer Diagnosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Targeting Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Prognosis Indication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Biocept, Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • KURABO INDUSTRIES LTD
  • PerkinElmer chemagen Technologie GmbH
  • Biodesix
  • Guardant Health
  • QIAGEN
  • Sequenom, Inc.
  • Agilent Technologies, Inc.
  • Fluxion Biosciences Inc.
  • Natera, Inc.
  • Agena Bioscience, Inc.
  • Paragon Genomics, Inc.
  • Lucence Health Inc.
  • Eurofins Genomics
  • Thermo Fisher Scientific

11. Section

  • Research Methodology
  • About Us